<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677053</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-442_202</org_study_id>
    <secondary_id>U1111-1112-5867</secondary_id>
    <nct_id>NCT00677053</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of multiple doses of&#xD;
      TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome&#xD;
      (unstable angina, myocardial infarction).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute coronary syndrome, including myocardial infarction with or without ST-segment elevation&#xD;
      and stable or unstable angina, is acknowledged to represent collectively a major global&#xD;
      healthcare problem. Despite existing treatments, the rates of patient mortality, myocardial&#xD;
      infarction and hospital readmissions during follow-up remain very high.&#xD;
&#xD;
      Due to its critical role in propagating the blood coagulation cascade, activated factor X now&#xD;
      is considered to be a major therapeutic target in the development of novel antithrombotic&#xD;
      therapy by blocking thrombin generation and attenuating the formation of fibrin. Therefore,&#xD;
      activated factor X inhibitors, exhibiting either indirect or direct modes of action, are&#xD;
      among the novel agents under investigation in the treatment of acute coronary syndrome.&#xD;
&#xD;
      This study will evaluate the safety and tolerability of TAK-442 compared with placebo in&#xD;
      post-acute coronary syndrome subjects who are also receiving standard antiplatelet and other&#xD;
      cardiovascular therapy.&#xD;
&#xD;
      Individuals who want to participate in this study will be required to provide written&#xD;
      informed consent. Study participation is anticipated to be approximately 3.5 months. Multiple&#xD;
      procedures will occur at each visit which may include fasting, blood collection, urine&#xD;
      collection, physical examinations, electrocardiograms and bilateral venogram.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Major Bleeding Events defined by the Thrombolysis in Myocardial Infarction Scale.</measure>
    <time_frame>On Occurrence (Up to 24 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Cardiovascular Mortality, non-fatal Myocardial Infarction, non-fatal Stroke, or Myocardial Ischemia requiring hospitalization.</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Myocardial Infarction.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Stroke.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Ischemia requiring hospitalization.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic Mortality.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Cardiovascular death, non-fatal Myocardial Infarction, or Myocardial Ischemia requiring hospitalization.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Cardiovascular death, non-fatal Myocardial Infarction, or non-fatal Stroke.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for Heart Failure.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of minor bleeding events defined by the Thrombolysis in Myocardial Infarction Scale.</measure>
    <time_frame>On Occurrence (Up to 24 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of minimal bleeding events defined by the Thrombolysis in Myocardial Infarction Scale.</measure>
    <time_frame>On Occurrence (Up to 24 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major, clinically significant non-major bleeding AND minor bleeding events as defined by the Secondary Bleeding Scale</measure>
    <time_frame>On Occurrence (Up to 24 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">2753</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>TAK-442 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 20 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 40 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 80 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 160 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-442 120 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Added with standard care for recurrent ischemic events</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 10 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 20 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 40 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 40 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 80 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 80 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 160 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-442</intervention_name>
    <description>Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>TAK-442 120 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Stages I, II &amp; III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has been hospitalized for acute coronary syndrome&#xD;
&#xD;
          -  Is able to initiate study drug if:&#xD;
&#xD;
               -  The index event occurred within the past 7 days (the date of initial&#xD;
                  hospitalization will be utilized for the date on which the index event occurred),&#xD;
                  and&#xD;
&#xD;
               -  The final acute medical or cardiac procedural intervention for the treatment of&#xD;
                  acute coronary syndrome was last administered or performed at least 36 hours&#xD;
                  before administration of the first dose of study drug.&#xD;
&#xD;
          -  Has at least 1 of the following additional ischemic risk factors:&#xD;
&#xD;
               -  Previous myocardial infarction.&#xD;
&#xD;
               -  The index event was an anterior myocardial infarction.&#xD;
&#xD;
               -  Presence of multivessel coronary disease&#xD;
&#xD;
               -  Left bundle branch block.&#xD;
&#xD;
               -  Left ventricular ejection fraction less than 40% at any time during&#xD;
                  hospitalization for the index event.&#xD;
&#xD;
               -  Killip class greater than or equal to II at any time during hospitalization for&#xD;
                  the index event.&#xD;
&#xD;
               -  History of symptomatic congestive heart failure&#xD;
&#xD;
               -  History of ischemic stroke or transient ischemic attack.&#xD;
&#xD;
               -  Presence of peripheral arterial obstructive disease.&#xD;
&#xD;
               -  Diabetes mellitus requiring medical therapy to maintain glycemic control.&#xD;
&#xD;
               -  Current smoker&#xD;
&#xD;
               -  Moderate renal impairment&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active must agree to use adequate&#xD;
             contraception, and can neither be pregnant nor lactating from Screening throughout the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has low body weight greater than 50 kg.&#xD;
&#xD;
          -  Has severe hypertension.&#xD;
&#xD;
          -  Has a known bleeding/clotting disorder.&#xD;
&#xD;
          -  Has acute pericarditis.&#xD;
&#xD;
          -  Has a history of intracranial or intraocular bleeding.&#xD;
&#xD;
          -  Has a history of gastrointestinal bleeding or gastric or duodenal ulceration.&#xD;
&#xD;
          -  Has a history of ischemic stroke or transient ischemic attack.&#xD;
&#xD;
          -  Has had major surgery, including coronary artery bypass graft or has undergone&#xD;
             non-major laparoscopic surgery or non-major minimally invasive surgery, within 2 weeks&#xD;
             prior to Randomization.&#xD;
&#xD;
          -  Has a history of cancer that has not been in remission for at least 5 years.&#xD;
&#xD;
          -  Has a condition for which long-term anticoagulation therapy is indicated or requires&#xD;
             ongoing use of other excluded medications.&#xD;
&#xD;
          -  Has severe renal dysfunction.&#xD;
&#xD;
          -  Has anemia or thrombocytopenia that has not resolved prior to Randomization.&#xD;
&#xD;
          -  Has alanine aminotransferase or total bilirubin levels greater than 2 times the upper&#xD;
             limit of normal, active liver disease or jaundice.&#xD;
&#xD;
          -  Has a history of illicit drug use or excessive alcohol intake.&#xD;
&#xD;
          -  Has any other serious disease or condition that would compromise subject safety,&#xD;
             increase the risk of bleeding, or make it difficult to successfully manage and follow&#xD;
             the subject according to the protocol.&#xD;
&#xD;
          -  Has received TAK-442 in a previous clinical study or as a therapeutic agent.&#xD;
&#xD;
          -  Has a history of hypersensitivity or allergies to other fXa inhibitors.&#xD;
&#xD;
          -  Has received any investigational compound within 30 days prior to Screening or is&#xD;
             currently participating in another study which entails the administration of an&#xD;
             investigational or marketed drug, supplement or intervention including, but not&#xD;
             limited to diet, exercise, lifestyle or invasive procedure.&#xD;
&#xD;
          -  Is required to take or intends to continue taking any disallowed medication, any&#xD;
             prescription medication, herbal treatment or over-the counter medication that may&#xD;
             interfere with evaluation of the study medication, including:&#xD;
&#xD;
               -  azole antifungal agents&#xD;
&#xD;
               -  cyclosporine&#xD;
&#xD;
               -  clarithromycin&#xD;
&#xD;
               -  HIV protease inhibitors&#xD;
&#xD;
               -  nefazodone&#xD;
&#xD;
               -  ritonavir&#xD;
&#xD;
               -  quinidine&#xD;
&#xD;
               -  amiodarone&#xD;
&#xD;
               -  verapamil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensecola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Algere</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haskovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pazardjik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Silistra</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chilliwack</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Charles Borromée</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Langen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bikaner</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calicut</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mangalor</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimoga</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thrissur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeonrabukdo</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hardenberg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targoviste</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sremska</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>CapeTown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodwood</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parow</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinelands</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Airdrie</city>
        <state>North Lanarkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <disposition_first_submitted>March 13, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 13, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 13, 2016</disposition_first_posted>
  <last_update_submitted>March 13, 2016</last_update_submitted>
  <last_update_submitted_qc>March 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unstable Angina</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Anticoagulant</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1H)-one</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

